-
1.发明公开公开(公告)号：US20240301078A1
公开(公告)日：2024-09-12
申请号：US18500799
申请日：2023-11-02
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , Christopher W.L. CHIU , Esther C.W. BREIJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
IPC: C07K16/28 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/704 , A61K39/00 , A61K39/395 , A61P35/00 , C07K16/46
CPC classification number: C07K16/2887 , A61K31/475 , A61K31/573 , A61K31/675 , A61K31/704 , A61K39/3955 , A61P35/00 , C07K16/2809 , C07K16/468 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K2317/24 , C07K2317/31 , C07K2317/565
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
-
公开(公告)号：US20240174761A1
公开(公告)日：2024-05-30
申请号：US18500673
申请日：2023-11-02
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Rebecca X.M.S. VALENTIN , Daniela HOEHN , Marcia RIOS
CPC classification number: C07K16/2887 , A61P35/00 , C07K16/2809 , A61K2039/505 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/31
Abstract: Provided are methods of clinical treatment of Richter's syndrome in human subjects using a bispecific antibody which binds to CD3 and CD20.
-
3.发明公开公开(公告)号：US20240034812A1
公开(公告)日：2024-02-01
申请号：US18025203
申请日：2021-09-10
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , Christopher W.L. CHIU , Esther C.W. BREIJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/565 , C07K2317/31
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
-
4.发明公开公开(公告)号：US20230312759A1
公开(公告)日：2023-10-05
申请号：US18025208
申请日：2021-09-10
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , Patricia GARRIDO CASTRO
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/565 , C07K2317/31
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL ineligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of car regimen of gemcitabine and oxaliplatin (GemOx).
-
公开(公告)号：US20230312757A1
公开(公告)日：2023-10-05
申请号：US18025202
申请日：2021-09-10
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Jenny J. CHEN , Tahamtan AHMADI , Christopher W.L. CHIU , Esther C.W. BRElJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/565 , C07K2317/31
Abstract: Provided are methods of clinical treatment of chromic lymphoblastic leukemia (CLL) inhuman subjects using a bispecific-antibody which binds to CD3 and CD20.
-
Patent Agency Ranking
公开(公告)号：US20220112309A1
公开(公告)日：2022-04-14
申请号：US17559965
申请日：2021-12-22
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , Patricia Garrido CASTRO
IPC: C07K16/46 , C07K16/28 , A61P35/00 , A61K31/282
Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., relapsed and/or refractory DLBCL ineligible for autologous stem cell transplant) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of gemcitabine and oxaliplatin (GemOx).
-
7.发明公开公开(公告)号：US20230312758A1
公开(公告)日：2023-10-05
申请号：US18025204
申请日：2021-09-10
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , cHRISTOPHER W.L. CHIU , Esther C.W. BREIJ , Ida HIEMSTRA , Maria N. JURE-KUNKEL
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/565 , C07K2317/31
Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.
-
公开(公告)号：US20230227570A1
公开(公告)日：2023-07-20
申请号：US17923317
申请日：2021-05-07
Applicant: GENMAB A/S
Inventor： Tahamtan AHMADI , Manish GUPTA , Tommy R. LI , Roberto OLIVERI , Dena DEMARCO , Ida HIEMSTRA , Christopher CHIU , Brian ELLIOTT , Ada AZARYAN
CPC classification number: C07K16/2887 , C07K16/2809 , A61P35/00 , C07K2317/31 , A61K39/00
Abstract: The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).
-
9.发明申请公开(公告)号：US20220112300A1
公开(公告)日：2022-04-14
申请号：US17558404
申请日：2021-12-21
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , Christopher W. L. CHIU , Esther C.W. BREIJ
IPC: C07K16/28 , A61K31/4184 , A61P35/00
Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
-
10.发明公开公开(公告)号：US20230357440A1
公开(公告)日：2023-11-09
申请号：US18025205
申请日：2021-09-10
Applicant: GENMAB A/S
Inventor： Brian ELLIOTT , Tahamtan AHMADI , Christopher W.L. CHIU , Esther C.W. BREIJ
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/565 , C07K2317/31 , C07K2317/24 , C07K2317/52
Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and bendamustine.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.016 seconds)
